DNA修復薬市場：薬剤タイプ別、用途別、投与経路別、流通チャネル別、地域別

世界のDNA修復薬市場は、2025年には80億5,000万米ドルと推定され、2032年には192億9,000万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は13.3%で成長する見込みです。

図.DNA修復薬市場シェア（%）、2025年地域別

DNA修復薬は、細胞が傷ついたDNAを識別して修復する能力を向上させることを目的としており、がんやゲノムの不安定性に関連するその他の疾患の治療に応用できる可能性があります。人体内のDNAは、環境暴露やその他の細胞プロセスによって自然に消耗し、時間の経過とともに切断やその他タイプの損傷を引き起こす可能性があります。通常の状況下では、細胞は進化的に最適化されたDNA修復経路を持ち、このような損傷を修復し、突然変異の蓄積を防ぎます。しかし、ある種の病状はDNA修復能力の欠損と関連しています。薬学的にDNA修復機構を強化することは、アンメットニーズへの対応に役立つ可能性があります。いくつかのバイオテクノロジー企業や大手製薬会社は、PARP、ATR、ATM、その他DNA損傷応答に関与する分子など、修復経路の主要タンパク質を標的とするDNA修復薬の研究を行っています。この萌芽的なセグメントは、がんや遺伝性疾患の精密治療の開発に有望です。

市場力学

世界のDNA修復薬市場の成長を牽引しているのは、世界のがん罹患率の上昇と、DNA損傷と様々な疾患発症との関連性に関する臨床的重要性の高まりです。さらに、DNA修復経路の分子標的を特定するための医薬品研究開発投資の増加や、様々な候補薬の臨床検査の進行は、市場参入企業に有利な機会を提供する可能性があります。しかし、DNA生物学に関連する複雑さや、オフ対象効果に関連する安全性リスクが、完全な理解と臨床応用の妨げとなる可能性があります。開発コストの高さが市場開拓の妨げになる可能性もあります。産業各社は、レスポンダー患者集団を選択するためのバイオマーカー戦略や、毒性を最小限に抑えつつ有効性を最大化するための併用療法アプローチに注力しています。将来の創薬努力により、がん以外の領域にも展望が広がる可能性があります。

本調査の主要特徴

• 本レポートでは、世界のDNA修復薬市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案のマトリックスについて説明しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界のDNA修復薬市場の主要企業をプロファイルしています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• DNA修復薬の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界のDNA修復剤市場分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界のDNA修復薬市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界のDNA修復薬市場、薬剤タイプ別、2020～2032年（10億米ドル）

• イントロダクション
• ニラパリブ（ゼジュラ）
• オラパリブ（リムパーザ）
• ルカパリブ（ルブラカ）
• タラゾパリブ（タルゼンナ）

第6章 世界のDNA修復薬市場、用途別、2020～2032年（10億米ドル）

• イントロダクション
• 卵巣がん
• 乳がん
• 前立腺がん
• 肺がん
• 腹膜がん
• その他

第7章 世界のDNA修復薬市場、投与経路別、2020～2032年（10億米ドル）

• イントロダクション
• 経口
• 非経口
• その他

第8章 世界のDNA修復薬市場、流通チャネル別、2020～2032年（10億米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界のDNA修復薬市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

第11章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第12章 参考文献と調査手法

• 参考文献
• 調査手法

Global Dna Repair Drugs Market is estimated to be valued at USD 8.05 Bn in 2025 and is expected to reach USD 19.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

Figure. Dna Repair Drugs Market Share (%), By Region 2025

DNA repair drugs aim to improve the ability of cells to identify and repair damaged DNA, which could have applications in treating cancer and other diseases related to genomic instability. DNA in the human body undergoes natural wear and tear from environmental exposures and other cellular processes that can cause breaks and other types of damage over time. Under normal circumstances, cells have evolutionarily optimized DNA repair pathways to fix such lesions and prevent mutations from accumulating. However, certain medical conditions are linked to deficiencies in DNA repair capacity. Enhancing DNA repair mechanisms pharmaceutically could help address unmet clinical needs. Several biotechs and big pharmaceutical firms are researching DNA repair drugs that target key proteins in repair pathways such as PARP, ATR, ATM and other molecules involved in DNA damage response. This budding field holds promise for developing precision medicines for cancer and genetic disorders.

Market Dynamics:

Global DNA repair drugs market growth is driven by rising cancer burden worldwide and growing clinical emphasis on DNA damage links to various disease pathogenesis. Furthermore, increasing pharmaceutical R&D investments to identify molecular targets in DNA repair pathways and ongoing clinical trials for various candidates can offer lucrative opportunities for market players. However, complexities associated with DNA biology and safety risks pertaining to off-target effects can hamper complete understanding and clinical translation. High costs of development can hamper the market growth. Industry players are focused on biomarker strategies to select responder patient populations and combination therapy approaches to maximize efficacy while minimizing toxicity. Future discovery efforts can expand the scope into non-oncology areas.

Key Features of the Study:

• This report provides in-depth analysis of the global DNA repair drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global DNA repair drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Genentech, Pfizer, AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation-

• By Drug Type
  • Niraparib (Zejula)
  • Olaparib (Lynparza)
  • Rucaparib (Rubraca)
  • Talazoparib (Talzenna)
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Application
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global DNA Repair Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global DNA Repair Drugs Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Niraparib (Zejula)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Olaparib (Lynparza)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rucaparib (Rubraca)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Talazoparib (Talzenna)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global DNA Repair Drugs Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ovarian Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Peritoneal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global DNA Repair Drugs Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global DNA Repair Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global DNA Repair Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AstraZeneca PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Novartis AG
  • Roche Holding AG
  • Agios Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • NMS Group

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact